Opyl Ltd. announced the appointment of Mr. Mark Ziirsen to the Opyl Board effective from September 21, 2020. Mark will also immediately become the new Opyl chair of the Audit and Risk Committee taking over from Mr. Damon Rasheed who will step into an executive director role leverage his expertise in the Artificial Intelligence space, particularly in relation to the Opyl Clinical Trial Predictor Tool. With the recent priority focus on accelerating the development of the Opyl Clinical Trial Predictor Tool, Damon is taking a more active role in supporting the advancement of technologies within the company, leveraging his expertise in AI.